ABUS
Q3 2026 EPS Estimate
$-0.03
Reports before open
Revenue Estimate
$450,000
FY2026E EPS$0.29
FY2029E EPS$0.34

Analyst Sentiment

Wall St. Consensus
Buy
10 analysts·Moderate coverage
70
Score
8 Buy (80%)2 Hold (20%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
880%
Hold
220%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$8.50
+95.9%
Consensus
$8.50
+95.9%
Bull
$8.50
+95.9%
12-Month Target Range10 analysts
$8.50$8.50$8.50
Current $4.34Consensus
Current Price
$4.34
Upside to Consensus
$4.16

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-97.04%
EPS
FY2028
Rev+1972.11%
EPS
FY2029
Rev+210.17%
EPS

Earnings Surprises

Recent Analyst Actions

Mar 17, 2022H.C. Wainwright
Arbutus Biopharma (ABUS) Stock: $8.50 Price Target And Buy Rating
Target:$8.50
+181.5%from $3.02